Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of [177Lu]Lu-EVS459 in Ovarian and Lung Cancers
NCT06376253Phase 1Terminated
- Sponsor
- Novartis
- Start
- Sep 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EVS459 in ovarian cancer and non-small cell lung cancer (NSCLC), sponsored by Novartis. Primary endpoints: Dose Limiting Toxicities at 6 weeks, Adverse Events and Serious Adverse Events at 42 months and 2 more. Started Sep 2024; status: terminated.
02
Drugs
EVS459
03
Conditions
ovarian cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06376253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06376253.